Welcome to our dedicated page for Tiziana Life Sciences Com SEC filings (Ticker: TLSA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Tiziana Life Sciences Ltd. (NASDAQ: TLSA) SEC filings page provides access to the company’s official regulatory disclosures as a foreign private issuer. Tiziana files its annual report on Form 20-F and furnishes current reports on Form 6-K under the Securities Exchange Act of 1934. These filings include press releases and formal updates on clinical, regulatory, and corporate developments.
For investors analyzing Tiziana’s clinical-stage biopharmaceutical business, Form 6-K reports are particularly important. Recent 6-Ks have furnished announcements about the dosing of the first patient in a Phase 2 randomized, placebo-controlled trial of intranasal foralumab in early Alzheimer’s disease, the initiation of enrolment for that trial, and the inclusion of the company’s ALS Phase 2 study in the ALS MyMatch Program. Other 6-K filings describe insider share purchases by the Chief Executive Officer, the withdrawal of a proposed public offering of common shares due to market conditions, interim financial results and corporate updates on lead programs, and participation in global healthcare conferences.
Tiziana also reports on safety and regulatory interactions for intranasal foralumab, including Development Safety Update Reports submitted to the U.S. Food and Drug Administration that summarize cumulative exposure and serious adverse event findings across neuroinflammatory indications. While these safety reports themselves are submitted to regulators, related information may be discussed in filed or furnished documents.
On this page, users can review Tiziana’s 20-F annual report for a comprehensive overview of its business and risk factors, and track ongoing 6-K filings for timely information on clinical milestones, strategic plans such as the intended spinout of IL-6 asset TZLS-501, and capital markets activities. Stock Titan enhances these filings with AI-powered summaries that explain key points from lengthy documents, highlight material disclosures, and make it easier to understand how each filing may relate to Tiziana’s intranasal immunotherapy programs and overall corporate strategy.
Tiziana Life Sciences Ltd filed a Form 6-K announcing positive preclinical results for its lead candidate, intranasal foralumab, in a Long COVID mouse model. The study showed that nasal anti-CD3 treatment reduced neuroinflammation, increased regulatory T cells in the brain, restored hippocampal neurogenesis, and improved short‑term memory.
The work, led by researchers at Yale and Brigham and Women’s/Harvard, used a mild respiratory SARS‑CoV‑2 model mimicking Long COVID without direct brain infection and included human observational data showing lower circulating Tregs in Long COVID patients. Tiziana highlights these findings as mechanistic support for intranasal foralumab, which has already shown favorable safety and signs of clinical benefit in an expanded access program and is being tested in a Phase 2a trial in non‑active secondary progressive multiple sclerosis.
Tiziana Life Sciences Ltd has reported that a late-breaking poster on its Phase 2a study of intranasal foralumab in Multiple System Atrophy (MSA) has been accepted for presentation at the 7th World Parkinson Congress in Phoenix, Arizona, taking place May 24-27, 2026.
The poster will describe the ongoing TILS-025 trial, the first clinical investigation of intranasal anti-CD3 therapy in MSA, an aggressive neurodegenerative disorder with no approved disease-modifying treatments. The open-label study enrolls up to 10 subjects aged 30–85 who receive intranasal foralumab 50 μg per dose for 6 months.
Key measures include changes in microglial activation via [F-18]PBR06 TSPO PET imaging and MDS-UMSARS scores, along with MRI-based brain atrophy, autonomic function, quality-of-life outcomes, and blood and CSF immune biomarkers. The company also highlights ongoing intranasal foralumab programs in non-active secondary progressive multiple sclerosis and prior evidence of reduced neuroinflammation in other neurological conditions.
Tiziana Life Sciences Ltd filed a Form 6-K to share positive preclinical data on its nasal anti-CD3 approach, using intranasal foralumab, as a potential way to address neuroinflammation linked to aging and associated cognitive decline. In a preclinical aging model, nasal anti-CD3 reversed key aspects of brain aging and improved cognition.
The company explains that intranasal foralumab, a fully human anti-CD3 monoclonal antibody, stimulates regulatory T cells to reduce neuroinflammation. Tiziana notes that 14 patients with non-active secondary progressive multiple sclerosis in an expanded access program showed either disease improvement or stability within six months, and intranasal foralumab is also being evaluated in a Phase 2a trial and other neurodegenerative indications.
Tiziana Life Sciences Ltd director and more-than-10% owner Gabriele M. Cerrone filed an initial ownership report showing substantial holdings in the company’s common stock and options. The filing lists direct ownership of 44,654,830 shares of common stock.
It also shows options over 1,629,702 shares of common stock at an exercise price of $0.88 per share expiring on May 6, 2028, plus four option positions over 250,000 underlying shares each at an exercise price of $0.71 per share expiring on May 3, 2034. According to a footnote, these options are exercisable upon the achievement of certain performance conditions.
Tiziana Life Sciences reported new biomarker data for its lead candidate, intranasal foralumab, in non-active secondary progressive multiple sclerosis (na-SPMS) with progression independent of relapse activity (PIRA). In 10 patients, 14 paired assessments linked treatment to reduced cerebrospinal fluid (CSF) inflammation, increased neuroprotective proteomic pathways, and reduced microglial activation on [F-18]PBR06-PET scans.
Investigators described this as the first direct connection between PET changes and favorable CSF shifts during nasal foralumab treatment in this population, supporting its role in targeting smoldering CNS inflammation. Tiziana is running an ongoing randomized, double-blind, placebo-controlled Phase 2a trial in na-SPMS, with top-line data expected in the first half of 2026, and has dosed 14 expanded-access patients, all showing disease improvement or stability within 6 months.
Tiziana Life Sciences Ltd. is offering 8,800,000 common shares at $1.25 per share on a best efforts basis, with one warrant for each share. Each warrant allows the holder to buy one additional common share at $1.50 until July 16, 2026. The offering would generate gross proceeds of $8,800,000, and the company plans to use the funds, together with existing cash, primarily to complete Phase 2 clinical trials in non-active SPMS and MSA and to support broader development of its lead asset, foralumab.
Common shares outstanding are expected to be 127,259,131 after the offering, up from 118,851,954 as of June 30, 2025. The company highlights that investors will experience immediate dilution, estimating a $1.11 per-share dilution relative to adjusted net tangible book value. Management also notes its status as an emerging growth company and smaller reporting company, ongoing need for additional capital, and the historically volatile trading range of its Nasdaq-listed shares under the symbol TLSA.
Tiziana Life Sciences Ltd. is conducting a primary offering of 8,800,000 common shares at $1.25 per share, with each share paired with a warrant to buy one additional common share at $1.50 until July 16, 2026. The shares trade on Nasdaq under the symbol “TLSA”.
Gross proceeds are expected to be $8.8 million before expenses, and the company plans to use the cash, together with existing funds, mainly to complete its Phase 2 clinical trials in non-active secondary progressive multiple sclerosis (na-SPMS) and multiple system atrophy (MSA), and to support broader development of its lead drug foralumab and general corporate purposes. After the offering, Tiziana expects to have 127,259,131 common shares outstanding, so new investors will experience immediate dilution relative to net tangible book value and could face further dilution if warrants, options, or RSUs are exercised.
Tiziana Life Sciences filed a Form 6-K to highlight the peer-reviewed publication of its open-label study of intranasal foralumab in patients with non-active secondary progressive multiple sclerosis (na-SPMS). The study appears in Neurology Neuroimmunology & Neuroinflammation, a journal of the American Academy of Neurology, and reports comprehensive positive results previously shared on May 6, 2025.
The publication is described as the first na-SPMS study to integrate TSPO-PET imaging, proteomics, and clinical assessments, supporting a novel mechanism for targeting progression independent of relapse activity. Investigators note clinical stabilization, microglial PET findings, and biomarker changes that align with nasal foralumab’s proposed immune-modulating effects without broad systemic immunosuppression.
Foralumab, the only fully human anti-CD3 monoclonal antibody currently in clinical development, has been dosed intranasally in 14 na-SPMS patients under an expanded access program, with improvement or stability within six months in all patients. Tiziana is also running an ongoing randomized, double-blind, placebo-controlled Phase 2 trial in na-SPMS, with top-line data expected in the first half of 2026.
Tiziana Life Sciences Ltd closed a company-led registered direct offering of 7,040,000 ordinary shares at $1.25 per share, raising gross proceeds of $8.8 million. Each share includes one warrant to buy an additional ordinary share at $1.50, exercisable until July 16, 2026, for potential additional gross proceeds of about $10.56 million. The financing was conducted without an underwriter and was taken up by senior management and existing shareholders, including the CEO, who purchased 2,400,000 shares, and the Executive Chairman, who purchased 1,600,000 shares through an affiliated entity. The company states that the proceeds will enable it to complete its Phase 2 na‑SPMS and MSA clinical trials and reach top-line data readouts.
Tiziana Life Sciences Ltd. is conducting a primary offering of common shares on a best efforts basis at $1.25 per share. For every common share purchased, investors receive one warrant to buy an additional common share at $1.50 at any time up to July 16, 2026.
The company estimates net proceeds of about $6.5 million, with no placement agent fees, to be used mainly to fund clinical development of its lead drug foralumab in non-active secondary progressive multiple sclerosis, Alzheimer’s disease and multiple system atrophy, plus working capital and general corporate purposes. Tiziana notes this financing will not be enough to complete its clinical programs and that further capital will be required.
As of June 30, 2025, the company had 118,851,954 common shares outstanding. The filing highlights risks including immediate dilution to new investors, potential share price volatility, and dependence on future financings to support ongoing trials and operations.